BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 28776424)

  • 1. Are peptide vaccines viable in combination with other cancer immunotherapies?
    Ohtake J; Sasada T
    Future Oncol; 2017 Aug; 13(18):1577-1580. PubMed ID: 28776424
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
    Mooradian MJ; Sullivan RJ
    Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
    Santana-Davila R; Chow LQ
    Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
    [No Abstract]   [Full Text] [Related]  

  • 4. The importance for immunoregulation for long-term cancer control.
    Fusi A; Dalgleish A
    Future Oncol; 2017 Aug; 13(18):1619-1632. PubMed ID: 28776411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges faced when identifying patients for combination immunotherapy.
    Ernstoff MS; Gandhi S; Pandey M; Puzanov I; Grivas P; Montero A; Velcheti V; Turk MJ; Diaz-Montero CM; Lewis LD; Morrison C
    Future Oncol; 2017 Aug; 13(18):1607-1618. PubMed ID: 28835114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal cancer vaccines: Tumor-associated antigens
    Wagner S; Mullins CS; Linnebacher M
    World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
    Colombo MP
    Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine.
    Kaumaya PT
    Future Oncol; 2020 Aug; 16(23):1767-1791. PubMed ID: 32564612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.
    Kranz LM; Beck JD; Grunwitz C; Hotz C; Vormehr M; Diken M
    Hum Vaccin Immunother; 2017 Oct; 13(10):2272-2279. PubMed ID: 28846471
    [No Abstract]   [Full Text] [Related]  

  • 11. An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer.
    Chu DT; Bac ND; Nguyen KH; Tien NLB; Thanh VV; Nga VT; Ngoc VTN; Anh Dao DT; Hoan LN; Hung NP; Trung Thu NT; Pham VH; Vu LN; Pham TAV; Thimiri Govinda Raj DB
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.
    Yan Y; Kumar AB; Finnes H; Markovic SN; Park S; Dronca RS; Dong H
    Front Immunol; 2018; 9():1739. PubMed ID: 30100909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Improving efficacy of cancer immunotherapy through targeting of macrophages].
    Peranzoni E; Donnadieu E
    Med Sci (Paris); 2019 Mar; 35(3):207-209. PubMed ID: 30931902
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer Nanomedicine: Lessons for Immuno-Oncology.
    Sengupta S
    Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
    Kyi C; Postow MA
    Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized peptide vaccine for treatment of advanced cancer.
    Sasada T; Yamada A; Noguchi M; Itoh K
    Curr Med Chem; 2014; 21(21):2332-45. PubMed ID: 24524766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy.
    Yu WD; Sun G; Li J; Xu J; Wang X
    Cancer Lett; 2019 Jun; 452():66-70. PubMed ID: 30902563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.
    Chung CK; Da Silva CG; Kralisch D; Chan A; Ossendorp F; Cruz LJ
    J Control Release; 2018 Sep; 285():56-66. PubMed ID: 30008371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic Cancer Vaccine and Immune Checkpoint Inhibitor].
    Mimura K; Kono K
    Gan To Kagaku Ryoho; 2017 Sep; 44(9):733-736. PubMed ID: 28912398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunotherapy: moving beyond current vaccines.
    Rosenberg SA; Yang JC; Restifo NP
    Nat Med; 2004 Sep; 10(9):909-15. PubMed ID: 15340416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.